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Abstract The present study was undertaken to investigate the
role of protein kinase A (PKA) in the control of human T-cell
leukemia virus type-I (HTLV-I) long terminal repeat (LTR)
expression, since this issue is still controversial. For this purpose
we employed two human T-cell lines; the Jurkat cells in which
long exposure to diBu-cAMP severely down-regulated the
catalytic subunit of PKA (PKA-C), and H-9 cells in which such
exposure markedly increased PKA-C level. Transient transfec-
tion assays revealed that addition of diBu-cAMP 1 h before or
after transfection profoundly increased HTLV-I LTR directed
CAT expression and synergistically enhanced its stimulation by
the viral transactivator tax gene product in both cell lines.
However longer exposure to diBu-cAMP before transfection
reduced LTR-CAT expression to below its basal level and
completely abolished its stimulation by tax in Jurkat cells, and
this diBu-cAMP inhibitory effect could be abrogated by co-
transfection of a PKA-C expressing vector. By contrast, in H-9
cells, this long exposure to diBu-cAMP continued enhancing
LTR-CAT expression and its tax-mediated transactivation, and
this stimulatory effect of diBu-cAMP could be diminished by the
PKA-specific inhibitor N-[2-(p-bromocinnamylamine)ethyl]-5-
isoquinolinsulfonamide (H-89). Notably, in the absence of
diBu-cAMP treatment H-89 reduced LTR-CAT expression to
below its basal level and prevented its stimulation by tax in both
cell lines. Together these findings indicate not only that cAMP-
activated PKA stimulates HTLV-I LTR expression and its
transactivation by tax, but even in the absence of PKA activating
signals the basal HTLV-I LTR expression as well as its
stimulation by tax are both dependent on a basal PKA activity.
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1. Introduction
Human T-cell leukemia virus type-I (HTLV-I) is the etio-
logic agent of adult T-cell leukemia (ATL) and tropical spastic
paraparesis/HTLV-I associated myelopathy (TSP/HAM) and
apparently of certain other clinical disorders [1]. However,
after infection the virus enters into a latent state, rendering
the infected individuals asymptomatic seropositive carriers, of
whom only a small proportion eventually develop an HTLV-I
related disorder 20^40 years later [1]. During this latency a
very low viral gene expression can be detected in the infected
T-cells of such carriers [2]. In contrast, TSP/HAM is charac-
terized by a high virus expression which seems to account for
most of the pathoimmunological manifestations of this syn-
drome [2]. Furthermore, the HTLV-I transactivator tax gene
product is widely considered to account for the viral leuke-
mogenicity due to its capacity of activating a wide variety of
cellular genes and acting as an oncogene in cell culture and
transgenic mice [1,3,4]. Therefore, generating an HTLV-I re-
lated disorder plausibly depends on viral gene activation in
the latently infected carriers. Understanding the control sys-
tem of HTLV-I expression, which involves complex interac-
tions between viral and cellular regulatory elements is essen-
tial for having an insight into the mechanisms underlying the
latency and reactivation of this virus.
Tax transactivates the viral promoter, located in the 5P-long
terminal repeat (LTR), via three repeats of incomplete but
highly homologous 21 bp enhancer sequences. Each of these
repeats consists of three functionally distinct domains desig-
nated A, B and C. Domain B, which is crucial for this trans-
activation, contains a TGACGT motif that is highly homol-
ogous to the cAMP responsive element (CRE), found in a
variety of genes that are regulated by the cAMP-activated
protein kinase A (PKA) through members of the CREB/
CREM/ATF transcription factor family [5]. This domain
binds, indeed, members of this family [5^10], which mediate
the e¡ect of tax on HTLV-I gene expression [3,11^13]. Do-
mains A and C are G-C rich and seem to control the relative
level of this tax e¡ect [8,14^16]. Although it is generally ac-
cepted that tax exerts this e¡ect through interaction with
members of the CREB/CREM/ATF family, there are indica-
tions that certain other cellular proteins may also mediate tax
interaction with the 21 bp repeats [15,17^19].
However, despite intensive research the mechanism of tax
e¡ect on the viral LTR is unclear yet, mainly because of the
numerous contradictory data related to tax interaction with
these transcription factors. For instance, certain studies dem-
onstrate that tax can interact only with CREB [16,20,21],
whereas others prove that tax can interact with every member
of the CREB/CREM/ATF family [7,9,22^24]. Certain inves-
tigators claim that tax can exert a stimulatory e¡ect through
these proteins only when CRE is in the context of the viral
21 bp repeat [8,11,12,16,20], whereas others demonstrate that
tax can activate also other CRE containing genes [3,23^25].
Certain reports show that tax enhances the binding of these
transcription factors to the HTLV-I CRE merely by facilitat-
ing their dimerization [21^24], while others provide evidence
that tax binds to the DNA together with the dimerized tran-
scription factors and stabilizes the DNA-protein complex
through interaction with the A and C domains of the 21 bp
repeats [14,16]. While certain data indicate that after binding
to the DNA/protein complex tax employs its own transcrip-
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tion activating domain [3,11,26,27], others demonstrate that it
requires the CREB binding protein (CBP) for exerting its
transactivatory e¡ect [23,28]. Particularly intriguing is the
con£ict over the very fundamental question of whether or
not PKA activity is required for these interactions of tax.
While certain data show that tax can activate both HTLV-I
LTR and other CRE containing promoters independently of
PKA activity [3], others prove that tax can use unphosphory-
lated CREB/CREM/ATF factors only for transactivation of
the HTLV-I LTR but needs their phosphorylation by PKA
for transactivation of other CRE containing genes [23,28].
Furthermore, there are studies showing that tax depends on
PKA activity even for activating the viral LTR [12,13].
cAMP activates PKA by binding to its two regulatory sub-
units (PKA-R) and dissociating, thereby, the two catalytic
subunits (PKA-C), which then migrate to the nucleus, where
they phosphorylate the target transcription factors [29,30].
Extended exposure to high intracellular cAMP level results
in either up- [31,32] or down-regulation [33^36] of PKA-C,
depending on the cell type. In order to shed more light on the
role of PKA in controlling HTLV-I expression we decided to
investigate the e¡ect of this PKA-C modulation on virus ex-
pression. For this purpose we used two di¡erent human T-cell
lines; the Jurkat cells in which long exposure to diBu-cAMP
severely down-regulated PKA-C and H-9 cells in which such
exposure markedly increased PKA-C level. Our results indi-
cate that activated PKA enhances the basal expression of
HTLV-I LTR as well as its transactivation by tax. Further-
more, we provide here evidence that even in the absence of
PKA activating signals the basal HTLV-I LTR expression as
well as its stimulation by tax are both dependent on a basal
PKA activity.
2. Materials and methods
2.1. Cells
Two human T-cell lines, Jurkat and H-9, were employed in this
study. The cells were grown in RPMI-1640 medium supplemented
with antibiotics and 10% fetal calf serum. All ingredients were pur-
chased from Kibbutz Beith Haemek, Israel.
2.2. Plasmids, DNA electroporation and CAT assay
Plasmid containing the complete HTLV-I LTR linked to the bac-
terial CAT reporter gene was a gift of Dr. K. Khazaie from the
German Cancer Center, Heidelberg, Germany. Plasmid expressing
the HTLV-I tax gene under CMV promoter was provided by Dr.
I.S.Y. Chen from UCLA, Los Angeles, USA and plasmid expressing
PKA-C was provided by Prof. Y. Shaul from the Weizman Institute,
Rehovot, Israel. Plasmids were introduced into the cells by electro-
poration and CAT activity was assayed as previously described [37].
The amount of the various transfected plasmids in the indicated com-
binations were: LTR-CAT 20 Wg, the tax expressing vector 10 Wg and
the PKA-C expressing vector 10 Wg per transfection.
It was important to estimate the e¡ect of pre-treatments with the
PKA activator diBu-cAMP, or with the PKA-speci¢c inhibitor N-[2-
(p-bromocinnamylamine)ethyl]-5-isoquinolinsulfonamide (H-89) [38],
on the plasmid uptake by the transfected cells. For this purpose we
prepared an 3H-labeled LTR-CAT plasmid by growing the host bac-
terial cells in the presence of 0.8 WCi/ml 3H-thymidine (60 mCi/mmol,
DuPont New England Nuclear Product) for overnight before isolating
the plasmid (51 000 cpm/Wg DNA). DNA uptake by the pre-treated
cells was estimated by including 1 Wg labeled plasmid in parallel iden-
tical transfection mixtures and 48 h after transfection the cells were
lysed and the DNA was pelleted from each lysate and assayed for its
radioactivity. The supernatant of each lysate was assayed for its pro-
tein content by Bio-Rad Protein Assay Reagent and the plasmid up-
take was normalized to the protein concentration of the respective
extracts.
2.3. PKA activity assay
PKA activity was assayed in the cell extracts by the Pierce Colori-
metric PKA Assay Kit (SpinZime Format, Rockford, IL, USA) with
cAMP present in the reaction mixture, according to the manufactur-
er’s instructions. This activity was normalized to the protein concen-
tration of each extract.
3. Results
3.1. Regulation of PKA-C by diBu-cAMP in Jurkat and
H-9 cells
In the present study we were interested to estimate the e¡ect
of PKA-C up- and down-regulation on the control of HTLV-I
expression. Therefore, we characterized the pattern of cAMP-
mediated regulation of PKA-C in various T-cell lines. This
was done by assaying PKA activity in cell extracts after var-
ious times of exposure to 1 mM diBu-cAMP. The enzymatic
activity was measured in a reaction mixture containing cAMP
and, therefore, it represented the total level of the PKA-C in
the extract (i.e. the PKA-C that was still bound to PKA-R
and the dissociated PKA-C). The results shown in Fig. 1
demonstrate a clear di¡erence in the pattern of PKA-C regu-
lation between Jurkat and H-9 cells. While extended exposure
to diBu-cAMP results in a time-dependent decline of the total
PKA-C level in Jurkat cells, it induces a continuous increase
of this level in H-9 cells. Therefore, we choose this pair of cell
lines for our subsequent experiments.
3.2. E¡ect of diBu-cAMP and H-89, added after DNA
transfection, on LTR-CAT expression and on its
transactivation by tax
In initial experiments HTLV-I LTR-CAT was transfected
either alone (Fig. 2A and C) or together with the tax express-
ing vector (Fig. 2B and D) into Jurkat (Fig. 2A and B) or H-9
(Fig. 2C and D) cells. Where indicated, diBu-cAMP was
added 2 h after transfection, whereas the PKA-speci¢c inhib-
itor H-89 was added 1 h earlier to ensure its uptake before
diBu-cAMP. These experiments demonstrated that diBu-
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Fig. 1. Up- and down-regulation of PKA-C in H-9 and Jurkat cells.
H-9 (O) and Jurkat (a) cells were incubated with 1.0 mM diBu-
cAMP for the indicated times and their extracts were analyzed for
PKA activity as described in Section 2. The enzymatic activity is
presented as fold of the activity measured in the respective diBu-
cAMP untreated control cells. The data represent the average of
four replicates þ S.D.
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cAMP stimulated LTR-CAT expression in both cell lines and
that this stimulation was abolished by H-89. The inhibitor
alone moderately reduced the LTR basal expression. They
also showed that diBu-cAMP synergistically enhanced the
transactivatory e¡ect of tax. Interestingly, the level of LTR-
CAT expression in the presence of the combination of tax and
diBu-cAMP was reduced by H-89 to markedly below the level
observed with tax alone. Moreover, even in the absence of
diBu-cAMP this inhibitor markedly reduced both the basal
LTR-CAT expression as well as its stimulation by tax. How-
ever, of particular note is that despite the di¡erent diBu-
cAMP-mediated regulation of PKA-C elicited by these two
cell lines, both gave practically the same results under all these
experimental conditions. This indicates that addition of diBu-
cAMP after transfection is inadequate to demonstrate the
e¡ect of the PKA-C up- or down-regulation.
3.3. E¡ect of PKA up- and down-regulation before DNA
transfection on LTR-CAT expression and on its
transactivation by tax
In the next experiments Jurkat and H-9 cells were exposed
to diBu-cAMP for increasing time and then were transfected
with LTR-CAT alone or LTR-CAT+tax. DiBu-cAMP re-
mained in the medium after transfection to avoid restoration
of PKA-C to its initial level. These experiments revealed that
diBu-cAMP pre-treatment of Jurkat cells for 1 h before trans-
fection still stimulated the expression of LTR-CAT (Fig. 3A).
Moreover, this short pre-treatment synergistically enhanced
the activation of this construct by tax (Fig. 3B). However,
longer diBu-cAMP pre-treatment of these cells gradually re-
duced LTR-CAT expression to below its basal level (Fig. 3A),
and almost completely abolished the stimulatory e¡ect of tax
(Fig. 3B). By contrast, in H-9 cells, this long pre-treatment
stimulated LTR-CAT expression (Fig. 3A) and synergistically
enhanced its transactivation by tax (Fig. 3B) throughout the
entire time range of these experiments.
To check the possibility that these results merely re£ect an
e¡ect of these pre-treatments on the DNA uptake by the cells
we added 1 Wg of 3H-labeled LTR-CAT containing plasmid to
transfection mixtures similar to those of the experiments
shown in Fig. 3 and measured the DNA uptake as described
in Section 2. The di¡erent samples varied by up to þ 12%
from the average uptake determined for each cell line
(32 200 cpm/mg extract protein for Jurkat cells and 27 400
cpm/mg extract protein for H-9 cells ; data not shown), thus
excluding such an artifact.
3.4. E¡ect of PKA-C expressing vector on LTR activation by
tax in diBu-cAMP pre-treated Jurkat cells
To determine whether the inhibitory e¡ects of the extended
diBu-cAMP pre-treatment observed in Jurkat cells resulted
from the PKA-C down-regulation, these cells were pre-treated
with diBu-cAMP for 24 h and then transfected with LTR-
CAT alone, LTR-CAT+PKA-C, LTR-CAT+tax and LTR-
CAT+tax+PKA-C. DiBu-cAMP remained in the culture me-
dium after transfection to avoid restoration of the intrinsic
PKA-C level and to prevent the association of the free cellular
PKA-R molecules with the PKA-C molecules expressed by the
transfected vector. These experiments demonstrated that re-
storing PKA activity by the PKA-C expressing vector restored
the stimulation of LTR-CAT expression in the diBu-cAMP
treated Jurkat cells (Fig. 4A). Moreover, this PKA-C restora-
tion also synergistically enhanced the stimulatory e¡ect of tax
in these cells (Fig. 4B). Introducing the PKA-C expressing
vector into diBu-cAMP untreated cells resulted in lower stim-
ulation of LTR-CAT expression (Fig. 4A) and only moder-
ately enhanced its transactivation by tax (Fig. 4B). These low-
er e¡ects can be explained by assuming that in the absence of
diBu-cAMP part of the PKA-C molecules encoded by the
exogenous vector are masked by cellular PKA-R molecules.
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Fig. 3. E¡ect of extended diBu-cAMP pre-treatment on LTR ex-
pression and on its transactivation by tax. Jurkat (E) and H-9 (a)
cells were pre-treated with diBu-cAMP for the indicated time and
then transfected with LTR-CAT alone (A) or together with tax ex-
pressing vector (B). CAT activity is expressed as fold of the speci¢c
activity measured in diBu-cAMP untreated respective control cells
transfected with LTR-CAT alone. Each point in the graphs repre-
sents the average respective results þ S.D. of ¢ve repeated experi-
ments.
Fig. 2. E¡ect of diBu-cAMP and H-89 added after transfection on
LTR expression and its transactivation by tax. Jurkat (A and B)
and H-9 (C and D) cells were transfected with LTR-CAT alone (A
and C) or together with tax expressing vector (B and D) and then
treated with diBu-cAMP and/or with H-89 as described in the text.
CAT activity was normalized to protein concentration of the respec-
tive extract and expressed as fold of the respective control cells. The
data represent the average þ S.D. of four repeated experiments with
Jurkat cells and ¢ve repeated experiments with H-9 cells.
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3.5. E¡ect of H-89 on LTR activation by tax in the
diBu-cAMP pre-treated H-9 cells
To examine the postulation that the stimulatory e¡ects of
diBu-cAMP pre-treatment observed in H-9 cells resulted from
the increasing PKA-C level, these cells were pre-treated with
diBu-cAMP in the absence or presence of the PKA inhibitor,
H-89 (45 WM), for 24 h before transfection. (H-89 was added
1 h earlier to ensure its penetration into the cells before diBu-
cAMP.) DiBu-cAMP and H-89 remained in the culture me-
dium after transfection to avoid subsequent restoration of
PKA to its initial status. These experiments demonstrated
that H-89 abolished the stimulatory e¡ect of diBu-cAMP
pre-treatment on LTR-CAT expression and reduced the ex-
pression of this construct in diBu-cAMP untreated cells to
below its basal level (Fig. 4C). Moreover this inhibitor
strongly lowered the stimulatory e¡ect of tax in diBu-cAMP
untreated cells and reduced LTR-CAT expression in cells ex-
posed to the combination of diBu-cAMP pre-treatment and
tax to below the level scored with tax alone (Fig. 4D).
4. Discussion
Long exposure to PKA activating signals leads to either
down- or up-regulation of the catalytic subunit of PKA, de-
pending on the cell type [31^36]. In attempt to shed more light
on the role of PKA in controlling HTLV-I gene expression we
used the Jurkat cell line, in which long exposure to diBu-
cAMP severely down-regulated PKA-C, and H-9 cell line, in
which such exposure profoundly up-regulated this catalytic
subunit. In all previous investigations of the e¡ect of cAMP
on HTLV-I LTR expression the adenylate cyclase activators
were added after DNA transfection [3,5,11^13].
Our ¢nding that both Jurkat and H-9 cells elicited the same
response of LTR-CAT expression and its tax-mediated trans-
activation to diBu-cAMP added after transfection proves that
such experimental conditions are inadequate for demonstrat-
ing the e¡ect of the up- or down-regulation of PKA-C.
Since under such conditions PKA was activated and stimu-
lated the relevant cellular transcription factors in the presence
of the reporter LTR construct, the expression of this construct
and its transactivation by tax were, as expected, equally en-
hanced in both cell lines. Thus the subsequent up- or down-
regulation of PKA-C could have, in these conditions, only a
marginal in£uence on the ultimate level of the reporter en-
zyme activity, since these PKA-C modulations plausibly be-
came e¡ective only shortly before assaying this activity. This
interpretation was further substantiated by our subsequent
experiments which readily illustrated the e¡ect of these
PKA-C modulations with cells in which the level of catalytic
subunit was already up- or down-regulated before transfec-
tion.
Pre-treatment of Jurkat cells with diBu-cAMP for 1 h be-
fore transfection, still profoundly stimulated LTR expression
and synergistically enhanced its transactivation by tax, most
likely because at this stage the level of active PKA-C was still
su⁄ciently high. However, longer diBu-cAMP pre-treatment
before transfection progressively reduced LTR expression and
its stimulation by tax in a time-dependent kinetics that corre-
lated with that of the PKA-C down-regulation. On the other
hand, similar exposure of H-9 cells to diBu-cAMP resulted in
a continuously increasing stimulation of LTR expression and
synergistic enhancement of its transactivation by tax. These
data point to a strict dependency of LTR-CAT expression as
well as of the tax e¡ect on PKA activity. This conclusion is
further supported by our observation that the inhibitory e¡ect
of the extended diBu-cAMP pre-treatment in Jurkat cells
could be reverted by co-transfection of a PKA-C overexpress-
ing vector, whereas the stimulatory e¡ect of this prolonged
diBu-cAMP noted in H-9 cells could be blocked by the
PKA-speci¢c inhibitor H-89. Moreover, our ¢nding that
LTR expression as well as its transactivation by tax are mark-
edly reduced by H-89 even in diBu-cAMP untreated cells
strongly suggests that both depend on a basal PKA activity
existing in the absence of PKA activating signals. This con-
clusion is consistent with other reports showing that HTLV-I
LTR activation by tax is much lower in PKA-de¢cient mutant
cells than in their wild-type counterparts [12,38]. Hwang et al.
[39] have reached to a similar conclusion for genes involved in
catecholamine synthesis. These authors have shown that the
expression of these genes is stimulated by PKA activating
signals and that in the absence of such signals their basal
expression is profoundly reduced by H-89.
It is of interest to discuss the possible roles of CREB and
CREM proteins in the outcomes of our present experiments.
All CREB isoforms act as activators of the CRE containing
genes. Their activity is enhanced by PKA-mediated phospho-
rylation of their kinase induced domain (KID) and negatively
regulated by speci¢c protein phosphatases [30]. CREM iso-
forms are highly homologous to CREB, especially in their
DNA binding and KID domains. However, with the excep-
tion of CREM-d, all other CREM isoforms lack a transcrip-
tion activating domain and are, therefore, considered to func-
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Fig. 4. E¡ect of diBu-cAMP pre-treatment, PKA-C expressing vec-
tor and H-89 on LTR expression and its transactivation by tax in
Jurkat and H-9 cells. Jurkat (A and B) and H-9 (C and D) cells
were pre-treated with diBu-cAMP for 24 h and then transfected
with LTR-CAT alone (A and C) or together with tax expressing
vector (B and D). Where indicated Jurkat cells were co-transfected
also with PKA-C expressing vector whereas H-9 cells received the
PKA inhibitor H-89 1 h before diBu-cAMP. CAT activity is pre-
sented as fold of the control activity measured in diBu-cAMP un-
treated cells transfected with LTR-CAT alone. The data represent
the averages þ S.D. of four repeated experiments.
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tion as repressors of cAMP regulated genes, either by com-
peting with CREB proteins on binding to CRE or by hetero-
dimerizing with CREB proteins and abolishing, thereby, their
transcription activation potential. The ultimate e¡ect of
cAMP on various CRE containing genes is thought to depend
on the relative a⁄nity of each CRE to each of these isoforms,
and on the quantitative ratio between the various CREB and
CREM isoforms, which varies in di¡erent tissues and cell
types [30]. Interestingly, Laurence et al. [23] have shown
that binding of certain CREM isoforms (CREM-K and
CREM-N) to the HTLV-I CRE allows tax to stimulate the
viral LTR expression, although they inhibit the e¡ect of tax
on other CRE containing genes.
Another important factor involved in cAMP related signal-
ling system is the so-called ‘inducible cAMP early repressor’
(ICER). This factor is encoded by an mRNA initiated from
an internal promoter within the CREM gene. This promoter
contains CRE and therefore can potentially be activated by
cAMP, although this activation seems to be tissue- and cell
type-speci¢c. ICER itself also binds to CRE, but acts to re-
press a variety of cAMP regulated genes, including its own,
after their initial activation by cAMP [30]. Bodor et al. [40]
have shown that transfection of ICER overexpressing vector
blocks tax-mediated transactivation of HTLV-I LTR.
By assuming that the a⁄nity of ICER to CRE is higher
than that of the unphosphorylated CREB or CREM proteins
but lower than that of their phosphorylated forms, it can be
postulated that the extent of LTR expression and of its trans-
activation by tax is modulated by the quantitative ratio be-
tween ICER level and the phosphorylated form of CREB/
CREM proteins. Bodor et al. [39] have shown that elevated
intracellular cAMP level induces ICER synthesis in mature
human T-cells. However, although PKA activation by diBu-
cAMP might induce ICER formation in both Jurkat and H-9
cells, as long as PKA activity is su⁄ciently high the phos-
phorylated CREB/CREM proteins are probably dominant
and stimulate LTR expression and its tax-mediated transacti-
vation. While this situation remains persistent in the diBu-
cAMP treated H-9 cells due to their PKA-C up-regulation,
the down-regulation of this subunit in Jurkat cells permits
dephosphorylation of CREB/CREM proteins and conse-
quently the inhibitory e¡ect of ICER on the viral LTR may
turn to be dominant. Furthermore, as noted before, without
PKA activating signal both LTR expression and the e¡ect of
tax are driven by the basal PKA activity of the cells. Under
such conditions there is no ICER in the cells and therefore
even the low basal level of CREB/CREM phosphorylation is
presumably su⁄cient to support the LTR activation by tax.
These hypotheses still require experimental evidence.
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